These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17679643)

  • 1. First- vs second-generation antipsychotic drugs in schizophrenia.
    Andrade C; Kharawala S
    Arch Gen Psychiatry; 2007 Aug; 64(8):978-9; author reply 979-80. PubMed ID: 17679643
    [No Abstract]   [Full Text] [Related]  

  • 2. CUtLASS confirms CATIE.
    Mintz J; Kopelowicz A
    Arch Gen Psychiatry; 2007 Aug; 64(8):978; author reply 979-80. PubMed ID: 17679644
    [No Abstract]   [Full Text] [Related]  

  • 3. The CATIE study.
    Teich J
    Am J Psychiatry; 2006 Mar; 163(3):554-5; author reply 555-6. PubMed ID: 16513894
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
    Tandon R; Nasrallah HA
    Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070
    [No Abstract]   [Full Text] [Related]  

  • 6. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based psychiatry: outcomes and decisions.
    Meyer JM
    South Med J; 2007 Sep; 100(9):861-2. PubMed ID: 17902282
    [No Abstract]   [Full Text] [Related]  

  • 8. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 9. [Priority for atypical antipsychotic drugs? Current studies clarify the issues].
    Dose M
    Psychiatr Prax; 2007 Jan; 34(1):46-9. PubMed ID: 17265252
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
    Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
    Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs of drugs for schizophrenia.
    Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
    Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

  • 13. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
    Montgomery JH; Byerly M; Carmody T; Li B; Miller DR; Varghese F; Holland R
    Control Clin Trials; 2004 Dec; 25(6):598-612. PubMed ID: 15588746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current pharmacotherapy of schizophrenia].
    Bitter I
    Orv Hetil; 2004 Jan; 145(3):105-9. PubMed ID: 15027331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotic medications and the treatment of schizophrenia.
    Lewis DA
    Am J Psychiatry; 2002 Feb; 159(2):177-9. PubMed ID: 11823256
    [No Abstract]   [Full Text] [Related]  

  • 16. Are new drugs for schizophrenia better than old ones?
    Gøtzsche P
    Lancet; 2009 Apr; 373(9671):1248; author reply 1249-50. PubMed ID: 19362667
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Rosenheck RA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1074-6. PubMed ID: 17015809
    [No Abstract]   [Full Text] [Related]  

  • 18. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
    Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
    Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trials design lessons from the CATIE study.
    Kraemer HC; Glick ID; Klein DF
    Am J Psychiatry; 2009 Nov; 166(11):1222-8. PubMed ID: 19797435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.